1
|
Wang S, Qi C, Ding J, Li D, Zhang M, Ji C, Jiang F, Teng F, Yu J, Qian X, Wang F, Shen L, Gao J, Yang Z, Zhang C, Zhu H. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging 2023; 50:2802-2817. [PMID: 37099132 DOI: 10.1007/s00259-023-06234-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 04/14/2023] [Indexed: 04/27/2023]
Abstract
PURPOSE Claudin 18.2 (CLDN18.2) is a reliable target for lesion detection and could have clinical implications for epithelial tumors, especially digestive system neoplasms. However, there is no predictive technology for accurate whole-body mapping of CLDN18.2 expression in patients. This study assessed the safety of the 124I-18B10(10L) tracer and the feasibility of mapping whole-body CLDN18.2 expression using PET functional imaging. METHODS The 124I-18B10(10L) probe was synthesized manually, and preclinical experiments including binding affinity and specific targeting ability were conducted after testing in vitro model cells. Patients with pathologically confirmed digestive system neoplasms were enrolled in an ongoing, open-label, single-arm, first-in-human (FiH) phase 0 trial (NCT04883970). 124I-18B10(10L) PET/CT or PET/MR and 18F-FDG PET were performed within one week. RESULTS 124I-18B10(10L) was successfully constructed with an over 95% radiochemical yield. The results of preclinical experiments showed that it had high stability in saline and high affinity in CLDN18.2 overexpressing cells (Kd = 4.11 nM). Seventeen patients, including 12 with gastric cancers, 4 with pancreatic cancers, and 1 with cholangiocarcinoma were enrolled. 124I-18B10(10L) displayed high uptake in the spleen and liver, and slight uptake in the bone marrow, lung, stomach and pancreas. The tracer uptake SUVmax in tumor lesions ranged from 0.4 to 19.5. Compared with that in lesions that had been treated with CLDN18.2-targeted therapy, 124I-18B10(10L) uptake was significantly higher in lesions that had not. Regional 124I-18B10(10L) PET/MR in two patients showed high tracer uptake in metastatic lymph nodes. CONCLUSIONS 124I-18B10(10L) was successfully prepared and exhibited a high binding affinity and CLDN18.2 specificity in preclinical studies. As an FiH CLDN18.2 PET tracer, 124I-18B10(10L) was shown to be safe with acceptable dosimetry and to clearly reveal most lesions overexpressing CLDN18.2. TRIAL REGISTRATION NCT04883970; URL: https://register. CLINICALTRIALS gov/ . Registered 07 May 2021.
Collapse
Affiliation(s)
- Shujing Wang
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Changsong Qi
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Jin Ding
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Dan Li
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Miao Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Congcong Ji
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Fangli Jiang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Fei Teng
- Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China
| | - Jie Yu
- Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China
| | - Xueming Qian
- Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China
| | - Feng Wang
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Lin Shen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China
| | - Jing Gao
- Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
| | - Zhi Yang
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
| | - Cheng Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
| | - Hua Zhu
- Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
| |
Collapse
|
2
|
Zhu H, Zhang H, Zhou N, Ding J, Jiang J, Liu T, Liu Z, Wang F, Zhang Q, Zhang Z, Yan S, Li L, Benabdallah N, Jin H, Liu Z, Cai L, Thorek DLJ, Yang X, Yang Z. Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2. Adv Sci (Weinh) 2021; 8:e2100965. [PMID: 34174177 PMCID: PMC8373167 DOI: 10.1002/advs.202100965] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 05/14/2021] [Indexed: 06/07/2023]
Abstract
Rapid progress has been made to identify and study the causative agent leading to coronavirus disease 2019 (COVID-19) but many questions including who is most susceptible and what determines severity remain unanswered. Angiotensin-converting enzyme 2 (ACE2) is a key factor in the infection process of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this study, molecularly specific positron emission tomography imaging agents for targeting ACE2 are first developed, and these novel agents are evaluated in vitro, in preclinical model systems, and in a first-in-human translational ACE2 imaging of healthy volunteers and a SARS-CoV-2 recovered patient (NCT04422457). ACE2 expression levels in different organs in live subjects are quantitatively delineated and observable differences are measured in the patient recovered from COVID-19. Surprising sites of uptake in the breast, reproductive system and very low uptake in pulmonary tissues are reported. This novel method can add a unique tool to facilitate SARS-CoV-2 related research and improve understanding of this enigmatic disease. Molecular imaging provides quantitative annotation of ACE2, the SARS-CoV-2 entry receptor, to noninvasively monitor organs impacted by the COVID-19.
Collapse
Affiliation(s)
- Hua Zhu
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Hanwen Zhang
- Department of RadiologyWashington University in St. Louis School of MedicineSt. LouisMO63110USA
- Program in Quantitative Molecular TherapeuticsWashington University in St. Louis School of MedicineSt. LouisMO63110USA
| | - Nina Zhou
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Jin Ding
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Jinquan Jiang
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Teli Liu
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Ziyu Liu
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
- Department of Nuclear MedicineThe Affiliated Hospital of Inner Mongolia Medical UniversityHohhot010050China
| | - Feng Wang
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Qian Zhang
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| | - Zhuochen Zhang
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Shi Yan
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)Department of Thoracic Surgery IIPeking University Cancer Hospital and InstituteBeijing100142China
| | - Lei Li
- Beijing Tongren Eye CenterBeijing Tongren HospitalCapital Medical UniversityBeijing Ophthalmology and Visual Scientific Key LabBeijing100730China
| | - Nadia Benabdallah
- Department of RadiologyWashington University in St. Louis School of MedicineSt. LouisMO63110USA
- Program in Quantitative Molecular TherapeuticsWashington University in St. Louis School of MedicineSt. LouisMO63110USA
| | - Hongjun Jin
- Guangdong Provincial Key Laboratory of Biomedical ImagingFifth Affiliated HospitalSun Yat‐sen UniversityZhuhaiGuangdong Province519000China
| | - Zhaofei Liu
- Medical Isotopes Research Center and Department of Radiation MedicineSchool of Basic Medical SciencesPeking University Health Science CenterBeijing100191China
| | - Lisheng Cai
- Molecular Imaging BranchNational Institute of Mental HealthNational Institutes of HealthBethesdaMD20892USA
| | - Daniel L. J. Thorek
- Department of RadiologyWashington University in St. Louis School of MedicineSt. LouisMO63110USA
- Program in Quantitative Molecular TherapeuticsWashington University in St. Louis School of MedicineSt. LouisMO63110USA
- Department of Biomedical EngineeringWashington University in St. LouisSt. LouisMO63110USA
| | - Xing Yang
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Zhi Yang
- Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research Evaluation of Radiopharmaceuticals (Ministry of Education/Beijing)Department of Nuclear MedicinePeking University Cancer Hospital and InstituteBeijing100142China
| |
Collapse
|